Dominik Mumberg, PhD (he/him/his)

Chief Scientific Officer
Adcendo ApS, Denmark

Chief Scientific Officer at Adcendo ApS.
25 years of experience in therapeutic innovation, translational sciences, pre-clinical and clinical development in oncology at Bayer & Schering AG.
Former VP, Oncology Research, and Translational Innovation Lead, with focus on ADCs, radiotherapies &  targeted therapies.
Fomrer member of Keystone Symposia Scientific Advisory Board.

Poster(s):

• (P 349) THE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR-ASSOCIATED PROTEIN (UPARAP) IS AN ATTRACTIVE TARGET FOR THE DEVELOPMENT OF ANTIBODY DRUG CONJUGATES FOR TREATMENT OF MESENCHYMAL MALIGNANCIES